Академический Документы
Профессиональный Документы
Культура Документы
DEMONSTRATING CAPABILITY TO COMPLY WITH A TEST PROCEDURE: THE CONTENT UNIFORMITY AND DISSOLUTION ACCEPTANCE LIMITS (CUDAL) APPROACH
Jim Bergum September 12, 2011
Potency (Average Drug Substance/Dosage Unit) Dissolution (% Drug Substance Released at Specified Time) Content Uniformity
USP <905> The degree of uniformity in the amount of the drug substance among dosage units.
All measurements of dosage units and criteria values are in percentage label claim (%LC). At each stage calculate the sample average X and the sample standard deviation s. Stage Number tested Pass stage if:
S1
10
|M - X | + 2.4s 15.0, where M is defined below. i) |M - X | + 2.0s 15.0 using all 30 results (S1 + S2) ii) No dosage unit is outside the maximum allowed range of 0.75*M to 1.25*M.
S2
20
M is defined as follows: (i) If X is less than 98.5%LC, then M = 98.5%LC. (ii) If X is between 98.5 and 101.5%LC, then M = X . (iii) If X is greater than 101.5%LC, then M = 101.5%LC.
Indifference Zone
Methodology Developed in Mid 80s Application: Process Validation (Show process does what it purports to do)
Request/Mission - Develop limits based on the process validation sample results that provide confidence that the testing standard samples will pass the testing standard.
Show Specific Quality Attributes will meet associated Testing Standards (eg: CU) Content Uniformity (units have similar amount of drug) Dissolution (units dissolve at required rate)
Mean (%LC)
Acceptance Limit Sample Results: Mean = 99.0 RSD (%) = 3.76
Meeting Relative Standard Deviation (RSD) Limit assures, with 90% confidence, that a future testing standard sample take from the batch has greater than a 95% chance of passing the UDU test.
Justification
6
Provides high assurance that batch meets regulatory standard Assurance increases with increased sample size. Will always need a standard to define Acceptable. Can be used for more than validation or product release (ex: evaluation of NIR methods for CU used in real time release). Tied directly to regulatory requirements Ensures compliance with 21 CFR 211.165(d) - Testing and Release for distribution Can be used as a tool to meet the expectations set forth by FDA's Process Validation Guidance
If acceptance limit sample passed limits, then with a pre-specified confidence level, the probability that a testing standard sample will pass the testing standard is greater than a pre-specified coverage value. Example: With 90% confidence, a future testing standard sample take from the batch has greater than a 95% chance of passing the testing standard.
Strategy Part 1
8
1. 2. 3.
Select Testing Standard (Ex: UDU) Assume probability distribution for individual observations
(ex: Normal with parameters (Mu) & (Standard Deviation))
4.
Assuming known distribution parameters, mathematically derive* the Lower Bound for each stage (Note: Each stage may have multiple criteria!) This is the hard part! Lower bound for overall test is the maximum of the individual stage lower bounds
*Bergum, J.S. and Hua Li, "Acceptance Limits for the New ICH USP 29 Content Uniformity Test," Pharmaceutical Technology, October 2007, pp. 90-100.
Batch Mean
Plan: Defined by the Testing Standard (Usually a random sample from the batch Sampling Plan 1)
Strategy Part 2
11
5. 6.
7.
8.
9.
Select Sampling Plan (1 or 2). Construct confidence interval for the distribution parameters based on user defined confidence level. Determine lower bound probabilities for each point in the confidence interval. Determine maximum probability across all points in confidence interval. Compare maximum probability to user defined coverage (Lower Bound).
( X Z*ULS/n, ULS)
Level (Usually 90 or 95%) Coverage Lower Bound - Desired Probability of future Testing Standard Samples passing Testing Standard (usually 95%). Sampling Plan/Sample Size Possible values specific to the Testing Standard (ex: Q for Dissolution, Target for Content Uniformity)
RSD(%) Limit 10 2.35 2.88 3.21 2.77 2.13 30 3.30 4.03 4.47 3.87 2.99 60 3.71 4.53 5.00 4.36 3.36
Sample Size Batch Mean Batch RSD 2 3 2 3 2 3 10 99.0 59.7 96.0 46.2 84.5 26.0 30 100.0 99.9 100.0 98.8 100.0 84.9 60 100.0 100.0 100.0 100.0 100.0 99.7
18
19
Result
Location
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Summary statistics
3 4
98.37 101.01 98.88 98.94 99.66 99.06 98.65 98.63 97.67 100.26 97.49 97.28 100.48 98.49 100.14 97.5 100.29 97.96 97.78 97.2 98.8 99.98 98.06 98.95 98.74 97.5 98.8 98.62 100.93 99.2
1
97.08 99.72 99.9 98.78 96.32 100.97 97.02 99.39 99.59 97.97 96.09 98.87 101.1 100.8 99.7
2
99.72 100.32 98.27 98.17 96.61 102.17 97.35 98.81 97.8 98.54 98.61 97.81 102.6 100.34 100.09
Mean
98.17 100.34 98.75 98.42 97.45 100.25 98.25 98.72 98.50 98.88 97.42 98.19 100.70 100.14 99.78
Variance
1.36 0.28 0.73 0.29 2.31 2.57 1.83 0.30 0.86 0.96 1.07 0.60 2.71 1.27 0.19
Std Dev
1.17 0.53 0.86 0.54 1.52 1.60 1.35 0.55 0.93 0.98 1.03 0.78 1.65 1.13 0.44
Descriptive Statistics Mean SE (within-location Std Dev) Standard deviation of location means
98.93 1.07 1.06
Standard Deviation of Location Means 0.9 SE 0.9 1.0 1.1 1.2 1.3
LL UL LL
1.0
UL LL
1.1
UL LL
1.2
UL
23
Sampling Plan (Loc x #/Loc) 15x4 100.0 100.0 100.0 99.6 100.0 98.6 100.0 90.4 15x2 100.0 100.0 100.0 98.2 100.0 97.9 99.9 81.9 10x2 100.0 96.6 99.7 81.7 100.0 82.3 94.8 53.3
1 100 2
1 2 1 2
1 97 2
1 2 1 2
Current Status
24
Original (Done)